TRANSFORMING THE TREATMENT
OF HEART DISEASE
Tenaya Therapeutics is a privately-held biopharmaceutical company backed by The Column Group. The Company was founded in 2016 by world-leading scientists from the Gladstone Institute’s Cardiovascular Division and the University of Texas Southwestern Medical Center.
Tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration.
Tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.
LATEST NEWS
Tenaya Therapeutics Strengthens Leadership Team with Appointment of Two Biopharmaceutical Industry Veterans
–Company Expands Scientific Advisory Board with Addition of Experts in Cardiovascular Genetics, Gene Therapy and Molecular Biology–
South San Francisco, Calif. – March 13, 2019 – Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, M.D., Ph.D., as Chief Medical Officer, and Kee-Hong Kim, Ph.D., as Senior Vice President of Manufacturing and Technical Operations.
Read MoreTenaya Therapeutics appoints Faraz Ali as Chief Executive Officer
South San Francisco, CA – July 30, 2018 – Tenaya Therapeutics, a preclinical-stage biotechnology company focused on discovery and development of novel therapies for heart failure, announced the appointment of Faraz Ali as Chief Executive Officer.“We are thrilled to bring Faraz on board as the new CEO,” said David Goeddel, Ph.D., Managing Partner at The Column Group and Chairman of the Board of Directors at Tenaya. “The Board felt his strategic vision, track record of relevant operational experience, and commitment to building a leading heart failure company over the long-term make him an outstanding choice for Tenaya.”
Read MoreUnlocking a cell’s potential to regenerate the heart
March 1, 2018 – ScienceDaily – Some organisms have a remarkable capacity for regenerating tissue. If a fish or salamander suffers heart damage, for instance, their cells are able to divide and successfully repair the injured organ. Imagine if you could do the same.In the embryo, human heart cells can divide and multiply, allowing the heart to grow and develop. The problem is that, right after birth, cardiomyocytes (heart muscle cells) lose their ability to divide. The same is true for many other human cells, including those of the brain, spinal cord, and pancreas.
Read MoreJoin Our Team
Are you ambitious, driven, energized by scientific innovation and committed to making a difference for patients suffering from heart disease? Do you value a culture grounded in science and teamwork? We are looking for experienced biopharmaceutical professionals and scientists to join the Tenaya team who want to help us advance our mission of using cutting-edge science and precision medicine to develop innovative therapies to transform the treatment of heart disease.